Peptides targeting the somatotropic axis: GHRHs, GHRPs, and IGF-1 analogs for growth hormone pathway research.
The growth hormone axis governs pituitary GH secretion and its downstream effector IGF-1. Key research compounds include CJC-1295 and Sermorelin, GHRH analogues that stimulate the anterior pituitary directly, and GHRP-6 and Ipamorelin, ghrelin-receptor agonists that trigger pulsatile GH release. IGF-1 LR3 is a recombinant, long-acting variant with an N-terminal extension studied for extended in vitro bioavailability, completing the GH axis research toolkit.
An evidence-based overview of CJC-1295 research: its modified GHRH analog structure, the Drug Affinity Complex mechanism, and what preclinical studies show about GH and IGF-1 signaling.
An evidence-based overview of Ipamorelin research: its selective GHS-R1a mechanism, comparison with GHRP-6, and what preclinical studies show about growth hormone secretion.
For in-vitro research use only. Not for human or veterinary use.
